Description | (+)-JQ-1isaBETbromodomaininhibitor,withIC50of77nM/33nMforthefirstandsecondbromodomain(BRD4(1/2)). |
---|---|
IC50&Target | IC50:77/33nM(BRD4(1/2))[1] |
InVitro | (+)-JQ1representsapotent,highlyspecificandKaccompetitiveinhibitorfortheBETfamilyofbromodomains.(+)-JQ1(100nM,48h)promptssquamousdifferentiationexhibitedbycellspindling,flatteningandincreasedexpressionofkeratin.(+)-JQ1(250nM)inducesrapidexpressionofkeratinintreatedNMC797cellscomparedto(-)-JQ1(250nM)andvehiclecontrols,asdeterminedbyquantitativeimmunohistochemistry.(+)-JQ1(250nM)elicitsatime-dependentinductionofstrong(3+)keratinstainingoftreatedNMC797cells,comparedto(-)-JQ1(250nM)[1].(+)-JQ1isapotentthienodiazepineinhibitor(Kd=90nM)oftheBETfamilycoactivatorproteinBRD4,whichisimplicatedinthepathogenesisofcancerviatranscriptionalcontroloftheMYConcogene.Dose-rangingstudiesof(+)-JQ1demonstratespotentinhibitionofH4Kac4bindingwithaIC50valueof10nMformurineBRDT(1)and11nMforhumanBRDT(1)[2]. |
InVivo | Pharmacokineticstudiesof(+)-JQ1areperformedinCD1micefollowingintravenousandoraladmiNISTration.Meanplasmaconcentration-timeprofilesof(+)-JQ1afterintravenousdosing(5mg/kg).Thepharmacokineticparametersforintravenous(+)-JQ1demonstrateexcellentdrugexposure(AUC=2090hr*ng/mL)andanapproximatelyonehourhalf-life(T1/2).Meanplasmaconcentration-timeprofilesof(+)-JQ1afteroraldosing(10mg/kg).Thepharmacokineticparametersfororal(+)-JQ1demonstrateexcellentoralbioavailABIlity(F=49%),peakplasmaconcentration(Cmax=1180ng/mL)anddrugexposure(AUC=2090hr*ng/mL)[1]. |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CellAssay [1] | (+)-JQ1isdissolvedinDMSOandstored,andthendilutedwithappropriatemedia(DMSO0.025%)beforeuse[1]. NUTmidlinecarcinomapatientcelllines(797and11060)areplatedinT-25flasksandgrowninDMEM(797)orRPMI(11060)containing10%fetalbovineserumand1%Penicillin/Streptomycin.Cellsaretreatedwitheither250nM(+)-JQ1,250nM(-)-JQ1ortheequivalentvolumeofDMSO(0.025%).Atthedesiredtimepoint,2×106cellsarespunat500×gfor5minutesat4°CandwashedwithPBS.PelletsareresUSPendedin1mLofcoldPBSandaddeddropwisewhilegentlyvortexingto9mL70%ethanolina15mLpolypropylenecentrifugetube.Fixedcellsarethenfrozenat-20°Covernight.Thenextday,cellsarecentrifugedat500×gfor10minutesat4°Candwashedwith3mLofcoldPBS.Cellsareresuspendedin500μLofpropidiumiodidestainingsolution(0.2mg/mLRNAseA,0.02mg/mLpropidiumiodide,0.1%Triton-XinPBS)andincubatedfor20minutesat37°C.SamplesarethentransferredtoiceandanalyzedonaBDFACSCantoII.HistogramsaregeneratedandcellcycleanalysisisperformedusingFlowJoflowcytometryanalysissoftware[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
AnimalAdministration [1][2] | (+)-JQ1isformulatedforintravenousinjectionin10%DMSOand10%HP-β-CD(Mice)[1]. Mice[1] | ||||||||||||||||
References |
|
MolecularWeight | 456.99 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula | C₂₃H₂₅ClN₄O₂S | ||||||||||||
CASNo. | 1268524-70-4 | ||||||||||||
Storage |
| ||||||||||||
Shipping | RoomtemperatureincontinentalUS;mayvaryelsewhere | ||||||||||||
Solvent&Solubility | DMSO:≥45mg/mL (+)-JQ-1(JQ1)isformulatedin10%DMSOand90%ofa10%2-hydroxypropyl-β-cyclodextrinsolution[3]. *"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> | ||||||||||||
References |
|
Purity:99.90%
SouthernBiotech/Goat Anti-Human Lambda-Alexa Fluor® 555/2070-32/1.0 mg
vectorlabs/Biotinylated Aleuria Aurantia Lectin (AAL)/B-1395/1 mg
vectorlabs/VECTASTAIN® Elite® ABC-HRP Kit (Peroxidase, Mouse IgG)/PK-6102/1 kit
vectorlabs/VECTASTAIN® Elite® ABC-HRP Kit (Peroxidase, Universal)/PK-6200/1 kit
vectorlabs/Unconjugated Musa Paradisiaca (Banana) Lectin (BanLec)/L-1410/5 mg
GiottoBiotech/Calmodulin N60D/5 mg/G02CLM60cn